Liquid Chromatography Column Separates Glycans
Thermo Fisher Scientific’s GlycanPac AXR-1 columns are designed for increased resolution of labeled and unlabeled glycans, and are compatible with fluorescence and mass spectrometry detection methods. This new column is designed to enable researchers to control the power of high-resolution accurate-mass (HRAM) mass spectrometry at high-throughput rates. The GlycanPac AXR-1 columns are designed to separate both labeled and native glycans based on the availability of samples.
According to the company, this new column helps users achieve increased resolution of glycans using HPLC, providing improved profile characterization. This allows characterization of glycans from monoclonal antibodies being developed for therapeutics.
Thermo Fisher Scientific
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.